--- title: "Are BASF’s (XTRA:BAS) Rising EPS And Flat Sales Recasting Its Earnings Quality Story?" type: "News" locale: "en" url: "https://longbridge.com/en/news/285798630.md" description: "BASF SE reported Q1 2026 sales of €16,020 million, slightly down from the previous year, while net income rose to €927 million and EPS increased to €1.06. Despite flat revenues, the company's earnings quality appears to improve due to a favorable product mix and sector trends. The reaffirmed annual dividend of €2.25 per share for 2025 highlights management's commitment to returning cash to shareholders. However, risks remain from weak European demand and overcapacity in the chemicals market. Analysts project €70.9 billion revenue and €3.3 billion earnings by 2028, with a fair value estimate of €48.50, indicating a potential downside from the current price." datetime: "2026-05-09T06:06:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285798630.md) - [en](https://longbridge.com/en/news/285798630.md) - [zh-HK](https://longbridge.com/zh-HK/news/285798630.md) --- # Are BASF’s (XTRA:BAS) Rising EPS And Flat Sales Recasting Its Earnings Quality Story? - In the first quarter of 2026, BASF SE reported sales of €16,020 million, slightly below the prior year, while net income rose to €927 million and basic earnings per share increased to €1.06 from €0.91. - This profit improvement, combined with a projected expansion of the global ammonium sulfate market where BASF is a key player, highlights how product mix and sector trends may be supporting higher earnings quality despite flat revenues. - With BASF’s higher quarterly earnings and stronger ammonium sulfate market outlook in mind, we’ll now examine how this shapes its investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. ## BASF Investment Narrative Recap To hold BASF, you need to believe its broad chemicals portfolio can convert modest sales into healthier profits, while managing energy, regulation and overcapacity pressures. The Q1 2026 beat on net income and EPS, despite slightly lower sales, supports the idea that mix and efficiency matter more than volume right now. However, this does not materially reduce the near term risk that weak European demand and base chemicals overcapacity, including in China, could still constrain margins. Against this backdrop, the reaffirmed annual dividend of €2.25 per share for 2025 stands out. It signals management’s willingness to return cash even while guidance points to only modest earnings and ongoing restructuring needs. For income focused shareholders, that payout can look appealing, but it also sharpens the question of how well future cash flows will cover both high investment requirements and consistent dividends if chemical markets stay soft. Yet behind these improving earnings, there is still a material risk investors should be aware of around... Read the full narrative on BASF (it's free!) BASF's narrative projects €70.9 billion revenue and €3.3 billion earnings by 2028. This requires 3.0% yearly revenue growth and an earnings increase of about €2.9 billion from €388.0 million today. Uncover how BASF's forecasts yield a €48.50 fair value, a 6% downside to its current price. ## Exploring Other Perspectives XTRA:BAS 1-Year Stock Price Chart Before this Q1 report, the most pessimistic analysts were assuming BASF's revenue would reach about €63.9 billion and earnings €2.1 billion by 2029, and they saw higher decarbonization and overcapacity risks as serious headwinds. Compared with the more balanced baseline narrative, their view is far more cautious about margins and long term demand, and this quarter's profit resilience could challenge or reinforce that stance once they revisit their assumptions. Explore 9 other fair value estimates on BASF - why the stock might be worth 30% less than the current price! ## Reach Your Own Conclusion Don't just follow the ticker - dig into the data and build a conviction that's truly your own. - A great starting point for your BASF research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. - Our free BASF research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BASF's overall financial health at a glance. ## Seeking Other Investments? Every day counts. These free picks are already gaining attention. See them before the crowd does: - The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free. - The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. - Outshine the giants: these 16 early-stage AI stocks could fund your retirement. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if BASF might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [BASFY.US](https://longbridge.com/en/quote/BASFY.US.md) - [BAS.DE](https://longbridge.com/en/quote/BAS.DE.md) ## Related News & Research - [BASF Targets Core Businesses for Further Cost Cutting](https://longbridge.com/en/news/287098958.md) - [US launches investigation into imports of Vietnamese chemical](https://longbridge.com/en/news/287007343.md) - [BASF SE: Dr. Dirk Elvermann, buy](https://longbridge.com/en/news/285913760.md) - [Bernstein Keeps Their Buy Rating on BASF SE (0BFA)](https://longbridge.com/en/news/285038698.md) - [BUZZ-HSBC lifts oil price assumptions, upgrades Shell and Repsol to 'buy'](https://longbridge.com/en/news/286738674.md)